Diseases [C] » Chemically-Induced Disorders [C25] » Drug-Related Side Effects and Adverse Reactions
Description
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals. MeSH
Hierarchy View
Subtype Terms (14)
Akathisia, Drug-Induced
3 drugs (2 approved, 1 experimental)
Anticholinergic Syndrome
1 approved drug
Cardiotoxicity
68 drugs (58 approved, 10 experimental)
Chemical and Drug Induced Liver Injury
33 drugs (25 approved, 8 experimental)
Chemotherapy-Related Cognitive Impairment
5 drugs (2 approved, 3 experimental)
Drug Hypersensitivity
5 approved drugs
Dyskinesia, Drug-Induced
13 drugs (8 approved, 5 experimental)
Injection Site Reaction
9 drugs (7 approved, 2 experimental)
Metabolic Side Effects of Drugs and Substances
6 drugs (5 approved, 1 experimental)
Ototoxicity
15 drugs (10 approved, 5 experimental)
Propofol Infusion Syndrome
1 approved drug
Serotonin Syndrome
2 approved drugs
Toxic Optic Neuropathy
3 drugs (2 approved, 1 experimental)
Approved Indicated Drugs (1)
Phase 4 Indicated Drugs (202)
acellular pertussis vaccine (including diptheria and tetanus toxoids) (Tripedia)
acetylsalicylic acid (aspirin)
ferric carboxymaltose (Injectafer)
haemophilus influenzae type b conjugate vaccine (HibTITER)
hepatitis b vaccine (recombinant) (Recombivax)
Inactivated polio virus - Enhanced (IPOL)
live oral poliovirus type 1, 2 and 3 (Trivalent oral polio vaccine - Sabin)
Phase 3 Indicated Drugs (127)
DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine (Pediarix)
ferric derisomaltose (Monoferric)
hydroxychloroquine (plaquenil)
Phase 2 Indicated Drugs (144)
allogeneic hematopoietic stem cells (Hemacord)
allogeneic natural killer cells
Anti-thymocyte Globulin (Rabbit) (Thymoglobulin)
autologous hematopoietic stem cells
Other Experimental Indicated Drugs (101)
Organization Involved with Phase 4 Indications (33)
Organization Involved with Phase 3 Indications (21)
Organization Involved with Phase 2 Indications (42)
Chinese Academy of Medical Sciences
European Organisation for Research and Treatment of Cancer
Grupo Espanol de Investigacion en Sarcomas
Guangdong Provincial Hospital of Traditional Chinese Medicine
Herbert Irving Comprehensive Cancer Center
Infan Industria Quimica Farmaceutica Nacional
Katholieke Universiteit Leuven
Organization Involved with Phase 1 Indications (22)
Organization Involved with Other Experimental Indications (18)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.